Karuna Therapeutics, Inc.

MapLight Therapeutics still has a few years’ worth of clinical trials left to complete to catch up with Bristol Myers Squibb’s potential blockbuster schizophrenia drug Cobenfy (xanomeline and trospium

The future direction for PureTech Health is again under the spotlight as a week after its chair stepped down, the company is now looking for a new CEO following the departure of Bharatt Chowrira. The

Welsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in

Bristol Myers Squibb made a $14bn gamble when it agreed to buy Karuna Therapeutics in late 2023 for its drug that was pending US Food and Drug Administration approval at the time of the acquisition. T